OBJECTIVE: To evaluate @entity876 , @entity470 ( @entity470 ) and @entity1722 oncogene expression and compare it with microvessel count (MVC) in determining the clinical outcome of stage Ib @entity957 ( @entity957 ) of the cervix. STUDY DESIGN: Immunostaining with @entity876 , @entity470 , @entity1722 and factor VIII antibodies was performed on @entity5 sections from 22 @entity1 (11 with @entity5 recurrence, 11 free of @entity5 after four years). The levels of oncogene expression were semiquantitatively graded (0-4). Microvessels were counted (per 200 x field) in areas of highest neovascularization. RESULTS: Eight of 11 @entity1 (72.7%) with recurrence expressed @entity470 as compared with 5 of 11 @entity1 (45.5%) free of disease. This difference is not significant (P = .39). An equal number of @entity1 with and without recurrence expressed @entity1722 . Five of 11 @entity1 (45.5%) with recurrence expressed @entity876 , as compared with 6 of 11 (54.5%) free of disease (P = 1.00). Eight of 11 @entity1 (72.7%) with recurrence had an MVC above 24 as compared with 2 of 11 @entity1 (18.2%) free of disease; this difference was statistically significant (P = .03). CONCLUSION: The expression of @entity470 , @entity876 and @entity1722 appears to have little prognostic value in stage Ib @entity957 of the uterine cervix. The prognostic value of MVC is in keeping with previous findings.

Oncogene expression and microvessel count in recurrent and nonrecurrent stage Ib XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'SCC'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity1722 :: ('2064', 'Gene') :: ['c-erbB-2', 'C-erbB-2']
@entity957 :: (MESH:D002294,Disease) :: ['squamous cell carcinoma of the cervix']
